demonstrated that BRAFV600E significantly reduced sodium-iodide symporter (NIS) expression in a subset of PTC patients without Hashimoto’s thyroiditis (P = 0.046) (45). This evidence concerns the gene SLC5A5 and Hashimoto thyroiditis.